Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Nordic Nanovector ASA ( (DE:8NN) ) has provided an announcement.
Thor Medical ASA has announced the approval of a national prospectus and the launch of a subsequent offering of up to 4,000,000 new shares at a subscription price of NOK 2.50 per share, aiming to raise up to NOK 10 million. The offering, managed by Arctic Securities AS and DNB Carnegie, will commence on 26 June 2025 and conclude on 3 July 2025, with the new shares expected to be traded on Euronext Oslo Børs by 15 July 2025.
More about Nordic Nanovector ASA
Thor Medical ASA is a Norwegian company specializing in the supply of radionuclides, particularly alpha particle emitters derived from thorium. Their innovative production process does not require irradiation or nuclear reactors, offering a reliable and environmentally friendly solution for the radiopharmaceutical industry. The company is headquartered in Oslo and is listed on the Oslo Stock Exchange under the ticker ‘TRMED’.
Average Trading Volume: 2,133,987
Current Market Cap: NOK778.2M
Find detailed analytics on 8NN stock on TipRanks’ Stock Analysis page.